Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer

ctDNA was evaluated as an objective marker of postoperative residual disease in primary advanced high-grade serous ovarian cancer.

Cancers (Basel)PubMed 40075633DOI 10.3390/cancers17050786